Primary Biliary Cirrhosis - Pipeline Review, H2 2016

Date: July 13, 2016
Pages: 90
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P13C44A28EFEN
Leaflet:

Download PDF Leaflet

Primary Biliary Cirrhosis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Primary Biliary Cirrhosis - Pipeline Review, H2 2016’, provides an overview of the Primary Biliary Cirrhosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis
  • The report reviews pipeline therapeutics for Primary Biliary Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Primary Biliary Cirrhosis therapeutics and enlists all their major and minor projects
  • The report assesses Primary Biliary Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Primary Biliary Cirrhosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Primary Biliary Cirrhosis Overview
Therapeutics Development
Pipeline Products for Primary Biliary Cirrhosis - Overview
Primary Biliary Cirrhosis - Therapeutics under Development by Companies
Primary Biliary Cirrhosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Primary Biliary Cirrhosis - Products under Development by Companies
Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development
AlbireoPharma
CymaBay Therapeutics, Inc.
Dr. Falk Pharma GmbH
Enanta Pharmaceuticals, Inc.
Genextra S.p.a.
GenKyoTex S.A.
GlaxoSmithKline Plc
MediGene AG
NGM Biopharmaceuticals, Inc.
Novartis AG
Shire Plc
TGV-Laboratories
Virobay Inc.
Primary Biliary Cirrhosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDP-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FFP-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GKT-831 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2330672 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hep-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJN-452 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
maralixibat chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBX-8025 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obeticholic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RhuDex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-825 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Primary Biliary Cirrhosis - Dormant Projects
Primary Biliary Cirrhosis - Product Development Milestones
Featured News & Press Releases
May 31, 2016: CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)
May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC
May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016
Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL
Apr 07, 2016: FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva (obeticholic acid) for the Treatment of PBC
Mar 30, 2016: Intercept Announces New OCA Data in PBC and NASH to be Presented at EASL 2016
Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn’s Disease with anti-CD40 Monoclonal Antibody
Dec 17, 2015: FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC
Nov 14, 2015: Intercept Presents New PBC Data at AASLD 2015
Nov 10, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis
Nov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015
Nov 03, 2015: Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting
Aug 31, 2015: FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
Jun 29, 2015: Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Marketing Approval of Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
Apr 13, 2015: Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Primary Biliary Cirrhosis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Primary Biliary Cirrhosis - Pipeline by AlbireoPharma, H2 2016
Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics, Inc., H2 2016
Primary Biliary Cirrhosis - Pipeline by Dr. Falk Pharma GmbH, H2 2016
Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals, Inc., H2 2016
Primary Biliary Cirrhosis - Pipeline by Genextra S.p.a., H2 2016
Primary Biliary Cirrhosis - Pipeline by GenKyoTex S.A., H2 2016
Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H2 2016
Primary Biliary Cirrhosis - Pipeline by MediGene AG, H2 2016
Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016
Primary Biliary Cirrhosis - Pipeline by Novartis AG, H2 2016
Primary Biliary Cirrhosis - Pipeline by Shire Plc, H2 2016
Primary Biliary Cirrhosis - Pipeline by TGV-Laboratories, H2 2016
Primary Biliary Cirrhosis - Pipeline by Virobay Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Primary Biliary Cirrhosis - Dormant Projects, H2 2016

LIST OF FIGURES

Number of Products under Development for Primary Biliary Cirrhosis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Biliary Cirrhosis - Pipeline Review, H2 2015 US$ 1,600.00 Jul, 2015 · 82 pages

Ask Your Question

Primary Biliary Cirrhosis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: